Literature DB >> 36274185

Smartphone-assisted guided self-help cognitive behavioral therapy for young people with distressing voices (SmartVoices): study protocol for a randomized controlled trial.

Marialuisa Cavelti1, Janko M Kaeser2, Stefan Lerch2, Stephanie Bauer3, Markus Moessner3, Thomas Berger4, Mark Hayward5,6, Michael Kaess2,7.   

Abstract

BACKGROUND: The long-standing view that auditory verbal hallucinations (AVH) or hearing voices is a sign of schizophrenia has been challenged by research demonstrating that they lie on a continuum ranging from normal to pathological experience related to distress and need for care. Hearing voices is more prevalent in adolescence than in later life, and hearing voices during adolescence indicates a risk for severe psychopathology, functional impairments, and suicide later in life. While there is increasing evidence for the efficacy of cognitive behavioral therapy for voices (CBTv) in adults with schizophrenia, research on psychological treatments for youth with distressing voices has been scarce. The aim of the current study is to examine the efficacy of CBTv, delivered using smartphone-based Ecological Momentary Assessment Intervention (EMI) in a transdiagnostic sample of youth.
METHODS: This is a superiority randomized controlled trial comparing 8 weeks of CBTv-based EMI in addition to treatment as usual (TAU) versus TAU only. TAU covers both no treatment and any form of psychiatric/psychological treatment. In the EMI condition, participants will be prompted twice a day to complete an EMA survey, and receive one intervention proposal per assessment. One-hundred fifty-four youth aged 14-25 years with distressing voices will be recruited from psychiatric clinics, local private practices, internet forums, and advertisements in print and social media. Before and after the intervention phase, participants will undergo a 9-day EMA. Single-blinded assessments will be conducted at baseline (T0) and at 3-month (T1) and 6-month (T2) follow-up. The primary outcome is the distress dimension of the Auditory Hallucinations subscale of the Psychotic Symptom Rating Scales at T1. Secondary outcomes include perceived hostile intention, power, and dominance of voices, passive, aggressive, and assertive relating to voices, and negative core beliefs about the self. DISCUSSION: Adolescence provides a crucial window of opportunity for early intervention for hearing voices. However, youth are notoriously reluctant help-seekers. This study offers a low-intensity psychological intervention for youth with distressing voices beyond diagnostic boundaries that, using a mobile technology approach, may match the treatment preferences of the generation of "digital natives." TRIAL REGISTRATION: German Clinical Trials Register DRKS00026243. Registered on 2 September 2021.
© 2022. The Author(s).

Entities:  

Keywords:  Adolescents; Auditory hallucinations; Ecological momentary assessment; Ecological momentary intervention; Experience sampling method; Just-in-time adaptive interventions; Therapy; Treatment; Voices; Youth

Year:  2022        PMID: 36274185     DOI: 10.1186/s13063-022-06846-0

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.728


  68 in total

1.  Psychotic experiences in a mental health clinic sample: implications for suicidality, multimorbidity and functioning.

Authors:  I Kelleher; N Devlin; J T W Wigman; A Kehoe; A Murtagh; C Fitzpatrick; M Cannon
Journal:  Psychol Med       Date:  2013-09-12       Impact factor: 7.723

2.  Auditory hallucinations across the lifespan: a systematic review and meta-analysis.

Authors:  K Maijer; M J H Begemann; S J M C Palmen; S Leucht; I E C Sommer
Journal:  Psychol Med       Date:  2017-09-28       Impact factor: 7.723

Review 3.  Auditory hallucinations in schizophrenia and nonschizophrenia populations: a review and integrated model of cognitive mechanisms.

Authors:  Flavie Waters; Paul Allen; André Aleman; Charles Fernyhough; Todd S Woodward; Johanna C Badcock; Emma Barkus; Louise Johns; Filippo Varese; Mahesh Menon; Ans Vercammen; Frank Larøi
Journal:  Schizophr Bull       Date:  2012-03-23       Impact factor: 9.306

4.  Children seeking help for auditory verbal hallucinations; who are they?

Authors:  Kim Maijer; Saskia J M C Palmen; Iris E C Sommer
Journal:  Schizophr Res       Date:  2016-10-27       Impact factor: 4.939

5.  Persistence and outcome of auditory hallucinations in adolescence: a longitudinal general population study of 1800 individuals.

Authors:  Ellen De Loore; Nicole Gunther; Marjan Drukker; Frans Feron; Bernard Sabbe; Dirk Deboutte; Jim van Os; Inez Myin-Germeys
Journal:  Schizophr Res       Date:  2011-02-18       Impact factor: 4.939

Review 6.  Examining the course of hallucinatory experiences in children and adolescents: a systematic review.

Authors:  Jose M Rubio; Julio Sanjuán; Ludwing Flórez-Salamanca; Manuel J Cuesta
Journal:  Schizophr Res       Date:  2012-03-30       Impact factor: 4.939

7.  Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study.

Authors:  R Poulton; A Caspi; T E Moffitt; M Cannon; R Murray; H Harrington
Journal:  Arch Gen Psychiatry       Date:  2000-11

8.  Auditory verbal hallucinations increase the risk for suicide attempts in adolescents with suicidal ideation.

Authors:  Junichi Fujita; Yuichi Takahashi; Atsushi Nishida; Yasuyuki Okumura; Shuntaro Ando; Miho Kawano; Koji Toyohara; Noriko Sho; Tatsuya Minami; Takashi Arai
Journal:  Schizophr Res       Date:  2015-07-29       Impact factor: 4.939

9.  Course of auditory vocal hallucinations in childhood: 11-year follow-up study.

Authors:  A A Bartels-Velthuis; J T W Wigman; J A Jenner; R Bruggeman; J van Os
Journal:  Acta Psychiatr Scand       Date:  2016-03-24       Impact factor: 6.392

Review 10.  Auditory verbal hallucinations and continuum models of psychosis: A systematic review of the healthy voice-hearer literature.

Authors:  David Baumeister; Ottilie Sedgwick; Oliver Howes; Emmanuelle Peters
Journal:  Clin Psychol Rev       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.